Syndax Pharmaceuticals Inc (SNDX) shareholders
Close on Nov 17, 2026Market cap $821.53MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Yue Tang Joint filing with Kynam Capital Management, LP (9.98%), Kynam Capital Management GP, LLC (9.98%) | 8,520,000 | 9.98% | 13G (passive) amendment | Dec 31, 2024 |
| BlackRock, Inc. | 6,744,049 | 7.80% | 13G (passive) amendment | Mar 31, 2025 |
| The Goldman Sachs Group, Inc. Joint filing with Goldman Sachs & Co. LLC (6.50%) | 5,581,828 | 6.50% | 13G (passive) amendment | Jun 30, 2025 |
| State Street Corporation | 4,653,172 | 5.20% | 13G (passive) | Sep 30, 2026 |
| Goldman Sachs & Co. LLC Joint filing with The Goldman Sachs Group, Inc. (5.20%) | 4,510,669 | 5.20% | 13G (passive) amendment | Mar 31, 2025 |
| Vanguard Capital Management | 4,457,143 | 5.05% | 13G (passive) | Mar 31, 2026 |
| Point72 Asset Management, L.P. Joint filing with Point72 Capital Advisors, Inc. (5.00%), Steven A. Cohen (5.00%) | 4,327,952 | 5.00% | 13G (passive) | Aug 15, 2025 |
| Point72 Capital Advisors, Inc. Joint filing with Point72 Asset Management, L.P. (5.00%), Steven A. Cohen (5.00%) | 4,277,847 | 5.00% | 13G (passive) | Jan 21, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SNDX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 9,020,006 | 10.10% | $197.18M | +765,580 | 0.00% |
| Kynam Capital Management, LP | 8,050,959 | 9.02% | $175.99M | – | 9.73% |
| Goldman Sachs Group Inc | 5,861,265 | 6.56% | $128.13M | +864,478 | 0.01% |
| State Street Corp | 5,658,424 | 6.34% | $123.69M | +1,228,348 | 0.00% |
| Bank Of America Corp /De/ | 4,045,094 | 4.53% | $88.43M | −204,742 | 0.01% |
| Vanguard Capital Management LLC | 3,927,892 | 4.40% | $85.86M | +105,313 | 0.00% |
| Deerfield Management Company, L.P. (Series C) | 3,779,900 | 4.23% | $82.63M | – | 0.86% |
| Eversept Partners, LP | 2,798,210 | 3.13% | $61.17M | −87,412 | 3.17% |
| Geode Capital Management, LLC | 2,584,136 | 2.89% | $56.50M | +427,078 | 0.00% |
| Hood River Capital Management LLC | 2,564,279 | 2.87% | $56.06M | +209,994 | 0.41% |
| Kingdon Capital Management, L.L.C. | 2,500,000 | 2.80% | $54.65M | – | 5.60% |
| Franklin Resources Inc | 2,286,499 | 2.56% | $49.98M | +136,420 | 0.01% |
| Millennium Management LLC | 2,053,960 | 2.30% | $44.90M | +1,854,436 | 0.02% |
| Vanguard Portfolio Management LLC | 1,921,796 | 2.15% | $42.01M | +184,655 | 0.00% |
| UBS Group AG | 1,893,750 | 2.12% | $41.40M | +740,088 | 0.01% |
| Elmind Capital, LP | 1,855,000 | 2.08% | $40.55M | – | 10.19% |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1,790,173 | 2.00% | $39.13M | +57,632 | 0.04% |
| Candriam S.C.A. | 1,696,040 | 1.90% | $37.04M | +770,708 | 0.17% |
| Soleus Capital Management, L.P. | 1,628,039 | 1.82% | $35.59M | −98,869 | 1.23% |
| Two Sigma Investments, LP | 1,578,125 | 1.77% | $34.50M | −1,471 | 0.02% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 242 | 108M | 100.0% | 37 / 96 | 77 / 39 | 18M | 10M |
| Q1 2026 | 247 | 101M | 100.0% | 45 / 99 | 68 / 25 | 20M | 13M |
| Q4 2025 | 230 | 100M | 100.0% | 34 / 82 | 81 / 28 | 15M | 17M |
| Q3 2025 | 228 | 101M | 100.0% | 42 / 82 | 71 / 28 | 16M | 17M |
| Q2 2025 | 216 | 102M | 100.0% | 31 / 85 | 67 / 32 | 18M | 17M |
| Q1 2025 | 218 | 101M | 100.0% | 32 / 90 | 60 / 26 | 23M | 20M |
| Q4 2024 | 215 | 98M | 100.0% | 36 / 88 | 61 / 29 | 29M | 20M |
| Q3 2024 | 210 | 90M | 100.0% | 39 / 85 | 59 / 24 | 18M | 9M |
| Q2 2024 | 196 | 88M | 99.0% | 26 / 88 | 58 / 18 | 11M | 17M |
| Q1 2024 | 189 | 95M | 100.0% | 30 / 81 | 55 / 18 | 11M | 8M |
| Q4 2023 | 177 | 92M | 100.0% | 36 / 82 | 43 / 34 | 34M | 15M |
| Q3 2023 | 175 | 73M | 81.3% | 20 / 76 | 59 / 11 | 11M | 9M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
195 funds held SNDX in Q2 2026, 55% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of SNDX | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 3,528,047 | 3.95% | $77.12M | 0.72% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 2,823,912 | 3.16% | $61.73M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,315,500 | 2.59% | $50.62M | 0.06% | Jun 30, 2026 |
| Hood River Small-Cap Growth Fund | 1,211,108 | 1.36% | $26.47M | 0.40% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,013,559 | 1.14% | $22.16M | 0.02% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 971,932 | 1.09% | $18.52M | 0.05% | Jul 31, 2026 |
| Franklin Small Cap Growth Fund | 928,025 | 1.04% | $17.68M | 0.72% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 821,881 | 0.92% | $17.97M | 0.12% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 582,815 | 0.65% | $11.10M | 0.96% | Jul 31, 2026 |
| iShares Biotechnology ETF | 571,670 | 0.64% | $12.50M | 0.14% | Jun 30, 2026 |
| Nuveen Quant Small Cap Equity Fund | 508,690 | 0.57% | $9.69M | 0.24% | Jul 31, 2026 |
| Loomis Sayles Small Cap Growth Fund | 499,843 | 0.56% | $10.93M | 0.48% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 449,122 | 0.50% | $8.80M | 0.02% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 442,134 | 0.50% | $8.66M | 0.05% | May 31, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 429,857 | 0.48% | $9.40M | 0.01% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Michael A. Metzger | Chief Executive Officer, Director | 517,218 | 0.58% | Jul 9, 2026 |
| Aaron Ondrey | Chief Financial Officer | – | – | Nov 12, 2026 |
| Nicholas A.J. Botwood | Head of R&D, CMO | 60,885 | 0.07% | Jun 12, 2026 |
| Keith A. Goldan | Chief Financial Officer | 139,252 | 0.16% | Jun 2, 2026 |
| Neil Gallagher | President, Head of R&D | 85,095 | 0.10% | Feb 12, 2025 |
| Dennis Podlesak | Director | 239,763 | 0.27% | Oct 30, 2026 |
| Aleksandra Rizo | Director | 49,000 | 0.05% | Feb 6, 2026 |
| Pierre Legault | Director | 114,000 | 0.13% | Feb 6, 2026 |
| Keith Katkin | Director | 124,000 | 0.14% | Feb 6, 2026 |
| Jennifer Jarrett | Director | 114,000 | 0.13% | Feb 6, 2026 |
| Martin H. Huber Jr. | Director | 103,000 | 0.12% | Feb 6, 2026 |
| William Meury | Director | 90,000 | 0.10% | Feb 7, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Dennis Podlesak Director | Oct 29, 2026 | Sale(10b5-1 plan) | −8,000 | $14.21 | $113.72K | 239,763 |
| Dennis Podlesak Director | Oct 29, 2026 | Option exercise | +8,000 | $11.81 | $94.48K | 247,763 |
| Michael A. Metzger Chief Executive Officer, Director | Jul 8, 2026 | Option exercise | +32,375 | $6.38 | $206.55K | 517,218 |
| Michael A. Metzger Chief Executive Officer, Director | Jul 8, 2026 | Sale(10b5-1 plan) | −32,375 | $24.24 | $784.77K | 484,843 |
| Nicholas A.J. Botwood Head of R&D, CMO | Jun 12, 2026 | Sale(10b5-1 plan) | −31,235 | $18.14 | $566.60K | 60,885 |
| Nicholas A.J. Botwood Head of R&D, CMO | Jun 12, 2026 | Option exercise | +31,235 | $13.82 | $431.67K | 92,120 |
| Nicholas A.J. Botwood Head of R&D, CMO | Jun 11, 2026 | Sale(10b5-1 plan) | −34,280 | $18.00 | $617.04K | 60,885 |
| Nicholas A.J. Botwood Head of R&D, CMO | Jun 11, 2026 | Option exercise | +22,515 | $13.82 | $311.16K | 95,165 |
| Keith A. Goldan Chief Financial Officer | Jun 1, 2026 | Sale | −1,177 | $18.99 | $22.35K | 139,252 |
| Michael A. Metzger Chief Executive Officer, Director | Jun 1, 2026 | Sale | −6,847 | $18.99 | $130.02K | 484,843 |
| Michael A. Metzger Chief Executive Officer, Director | Feb 9, 2026 | Sale | −17,159 | $21.03 | $360.85K | 491,690 |
| Keith A. Goldan Chief Financial Officer | Feb 9, 2026 | Sale | −3,410 | $21.03 | $71.71K | 140,429 |
| Michael A. Metzger Chief Executive Officer, Director | Feb 6, 2026 | Sale | −7,412 | $20.62 | $152.84K | 508,849 |
| Keith A. Goldan Chief Financial Officer | Feb 6, 2026 | Sale | −2,082 | $20.62 | $42.93K | 143,839 |
| Keith Katkin Director | Feb 4, 2026 | Award | +24,000 | – | – | 124,000 |
| Dennis Podlesak Director | Feb 4, 2026 | Award | +48,000 | – | – | 239,763 |
| Michael A. Metzger Chief Executive Officer, Director | Feb 4, 2026 | Award | +144,600 | – | – | 516,261 |
| Michael A. Metzger Chief Executive Officer, Director | Feb 4, 2026 | Award | +73,000 | – | – | 371,661 |
| Nicholas A.J. Botwood Head of R&D, CMO | Feb 4, 2026 | Award | +24,000 | – | – | 59,165 |
| Nicholas A.J. Botwood Head of R&D, CMO | Feb 4, 2026 | Award | +36,000 | – | – | 95,165 |
| Jennifer Jarrett Director | Feb 4, 2026 | Award | +24,000 | – | – | 114,000 |
| Keith A. Goldan Chief Financial Officer | Feb 4, 2026 | Award | +21,500 | – | – | 115,171 |
| Keith A. Goldan Chief Financial Officer | Feb 4, 2026 | Award | +30,750 | – | – | 145,921 |
| Aleksandra Rizo Director | Feb 4, 2026 | Award | +24,000 | – | – | 49,000 |
| Pierre Legault Director | Feb 4, 2026 | Award | +24,000 | – | – | 114,000 |
| Martin H. Huber Jr. Director | Feb 4, 2026 | Award | +24,000 | – | – | 103,000 |
| Keith A. Goldan Chief Financial Officer | Jan 30, 2026 | Other | +1,219 | $8.48 | $10.34K | 93,671 |
| Keith A. Goldan Chief Financial Officer | Dec 1, 2025 | Gift | −1,224 | – | – | 92,452 |
| Michael A. Metzger Chief Executive Officer, Director | Sep 8, 2025 | Option exercise | +157,307 | $10.90 | $1.71M | 455,968 |
| Michael A. Metzger Chief Executive Officer, Director | Sep 8, 2025 | Sale(10b5-1 plan) | −157,307 | $16.41 | $2.58M | 298,661 |
| Dennis Podlesak Director | Aug 18, 2025 | Option exercise | +19,200 | $7.20 | $138.24K | 210,963 |
| Dennis Podlesak Director | Aug 18, 2025 | Sale(10b5-1 plan) | −19,200 | $15.84 | $304.13K | 191,763 |
| Dennis Podlesak Director | Aug 15, 2025 | Option exercise | +19,200 | $7.20 | $138.24K | 210,963 |
| Dennis Podlesak Director | Aug 15, 2025 | Sale(10b5-1 plan) | −19,200 | $15.54 | $298.37K | 191,763 |
| Dennis Podlesak Director | Aug 14, 2025 | Option exercise | +19,200 | $7.20 | $138.24K | 210,963 |
| Dennis Podlesak Director | Aug 14, 2025 | Sale(10b5-1 plan) | −19,200 | $14.19 | $272.45K | 191,763 |
| Keith A. Goldan Chief Financial Officer | Jul 31, 2025 | Other | +1,226 | $8.43 | $10.34K | 93,676 |
| Keith A. Goldan Chief Financial Officer | Jul 16, 2025 | Sale | −1,296 | $9.29 | $12.04K | 92,450 |
| Michael A. Metzger Chief Executive Officer, Director | Jul 16, 2025 | Sale | −7,534 | $9.29 | $69.99K | 298,661 |
| Keith Katkin Director | May 19, 2025 | Buy | +10,000 | $9.11 | $91.10K | 100,000 |
| Keith A. Goldan Chief Financial Officer | May 19, 2025 | Buy | +3,000 | – | – | 93,746 |
| Martin H. Huber Jr. Director | May 19, 2025 | Buy | +5,000 | $8.99 | $44.95K | 79,000 |
| Nicholas A.J. Botwood Head of R&D, CMO | May 16, 2025 | Buy | +11,765 | $9.00 | $105.89K | 35,165 |
| Michael A. Metzger Chief Executive Officer, Director | Mar 14, 2025 | Option exercise | +6,074 | $7.20 | $43.73K | 306,195 |
| Michael A. Metzger Chief Executive Officer, Director | Mar 4, 2025 | Option exercise | +7,814 | $7.20 | $56.26K | 307,935 |
| Michael A. Metzger Chief Executive Officer, Director | Mar 4, 2025 | Sale(10b5-1 plan) | −7,814 | $15.05 | $117.60K | 300,121 |
| Neil Gallagher President, Head of R&D | Feb 10, 2025 | Sale | −4,618 | $15.50 | $71.58K | 85,095 |
| Michael A. Metzger Chief Executive Officer, Director | Feb 10, 2025 | Sale | −13,288 | $15.50 | $205.96K | 300,121 |
| Keith A. Goldan Chief Financial Officer | Feb 10, 2025 | Sale | −3,777 | $15.50 | $58.54K | 90,746 |
| Jennifer Jarrett Director | Feb 5, 2025 | Award | +25,000 | – | – | 90,000 |
| Pierre Legault Director | Feb 5, 2025 | Award | +25,000 | – | – | 90,000 |
| William Meury Director | Feb 5, 2025 | Award | +25,000 | – | – | 90,000 |
| Keith Katkin Director | Feb 5, 2025 | Award | +25,000 | – | – | 90,000 |
| Neil Gallagher President, Head of R&D | Feb 5, 2025 | Award | +18,500 | – | – | 66,313 |
| Neil Gallagher President, Head of R&D | Feb 5, 2025 | Award | +23,400 | – | – | 89,713 |
| Michael A. Metzger Chief Executive Officer, Director | Feb 5, 2025 | Award | +60,500 | – | – | 224,409 |
| Michael A. Metzger Chief Executive Officer, Director | Feb 5, 2025 | Award | +89,000 | – | – | 313,409 |
| Dennis Podlesak Director | Feb 5, 2025 | Award | +50,000 | – | – | 191,763 |
| Martin H. Huber Jr. Director | Feb 5, 2025 | Award | +25,000 | – | – | 74,000 |
| Aleksandra Rizo Director | Feb 5, 2025 | Award | +25,000 | – | – | 25,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Syndax Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 466 shares on Aug 25, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Dennis Podlesak Director | Oct 29, 2026 | 8,000 | $114.56K | Oct 29, 2026 | Exercise of Stock Options |
| Michael A. Metzger Director, Officer | Jul 8, 2026 | 32,375 | $752.40K | Jul 8, 2026 | Exercise of Stock Options |
| Nicholas A.J. Botwood Officer | Jun 12, 2026 | 31,235 | $566.69K | Jun 12, 2026 | Stock Option Exercise |
| Nicholas A.J. Botwood Officer | Jun 11, 2026 | 34,280 | $609.43K | Jun 11, 2026 | Open Market Purchase |
| Michael A. Metzger Officer, Director | Jun 1, 2026 | 6,847 | $130.03K | Jun 1, 2026 | Restricted Stock Vesting |
| Keith A. Goldan Officer | Jun 1, 2026 | 1,177 | $22.35K | Jun 1, 2026 | Restricted Stock Vesting |
| Michael A. Metzger Officer, Director | Feb 9, 2026 | 17,159 | $360.83K | Feb 9, 2026 | Restricted Stock Vesting |
| Keith A. Goldan Officer | Feb 9, 2026 | 3,410 | $71.71K | Feb 9, 2026 | Restricted Stock Vesting |
| Michael A. Metzger Officer, Director | Feb 6, 2026 | 7,412 | $152.84K | Feb 6, 2026 | Restricted Stock Vesting |
| Keith A. Goldan Officer | Feb 6, 2026 | 2,082 | $42.93K | Feb 6, 2026 | Restricted Stock Vesting |
| Michael A. Metzger Director, Officer | Sep 8, 2025 | 157,307 | $2.68M | Sep 8, 2025 | Exercise of Stock Options |
| Dennis Podlesak Director | Aug 18, 2025 | 14,400 | $226.66K | Aug 18, 2025 | Exercise of Stock Options |
| Dennis Podlesak Director | Aug 14, 2025 | 43,200 | $581.04K | Aug 14, 2025 | Exercise of Stock Options |
| Michael A. Metzger Officer, Director | Jul 16, 2025 | 7,534 | $69.96K | Jul 16, 2025 | Restricted Stock Vesting |
| Keith A. Goldan Officer | Jul 16, 2025 | 1,296 | $12.03K | Jul 16, 2025 | Restricted Stock Vesting |
See a number that looks wrong?